Vomiting
Return to Library
Recent findings in life sciences described by researchers from Mayo Clinic
2009 AUG 24 - (NewsRx.com) -- According to recent research published in the journal Expert Opinion on Investigational Drugs, "Heat shock protein 90 (HSP90) is the core of a multi-chaperone complex critical for the folding, trafficking, and stabilization of many client proteins that are involved in tumor cell proliferation, survival, and angiogenesis. Targeting HSP90 results in degradation of these client proteins." "Data supporting the development of tanespimycin, which targets HSP90, are reviewed. Clinical data available for tanespimycin development are presented. Tanespimycin can be given safely at biologically active doses with mild toxicity such as nausea, vomiting, diarrhea, and fatigue. Although single-agent studies have shown limited activity, combinations of tanespimycin with bortezomib or trastuzumab have suggested promising avenues of further evaluation in multiple myeloma and breast cancer, respectively. Further development of HSP90-targeted strategies include testing of novel chemical structures having better solubility and stability and the potential for oral administration," wrote C. Erlichman and colleagues, Mayo Clinic. The researchers concluded: "Targeting of HSP90 in combination with other heat shock proteins, such as HSP70 or HSP27, may be an alternative strategy that warrants further exploration.." Erlichman and colleagues published their study in Expert Opinion on Investigational Drugs (Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opinion on Investigational Drugs, 2009;18(6):861-868). For additional information, contact C. Erlichman, Mayo Clinic, Center Cancer, Dept. of Oncology, Rochester, MN 55905, USA. The publisher's contact information for the journal Expert Opinion on Investigational Drugs is: Informa Healthcare, Telephone House, 69-77 Paul Street, London EC2A 4LQ, England. Keywords: United States, Rochester, Life Sciences, Oncology, Tumor Vascularization, Angiogenesis, Vomiting, Nausea, Cell Proliferation, Mayo Clinic. This article was prepared by Pharma Business Week editors from staff and other reports. Copyright 2009, Pharma Business Week via NewsRx.com.
|
